Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. The Company's clinical programmes target large addressable markets including, cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") and metabolic conditions such as obesity with the development of an oral encapsulated glucagon-like peptide GLP-1R agonist.

Jeremy Skillington, CEO

Jeremy Skillington, PhD began his biotechnology career in the Business Development group of Genentech, Inc in California in 2002. At Genentech he was responsible for executing over 40 licensing, investment and collaboration transactions. Returning to Ireland in 2009, Jeremy led Business Development and was a member of the Senior Management team at Opsona Therapeutics Ltd before becoming a founder and CEO of immuno-oncology company TriMod Therapeutics Ltd. In 2014 Jeremy joined German life science investment fund HS Lifesciences GmbH to provide start-up and business development support to portfolio companies ImmunoQure AG and Ethris GmbH. Jeremy joined Inflazome Ltd on its founding in 2016 and as VP of Business Development was instrumental in their acquisition by Roche in September 2020 for €380m upfront and significant downstream milestones for their portfolio of NLRP3 inflammasome inhibitors. He has been CEO of publicly listed Poolbeg Pharma Plc since June 2021.

Jeremy studied Biochemistry at the University of Galway, Ireland where he was awarded his PhD. He performed post-doctoral research at the University of California, San Francisco in the lab of Prof Rik Derynck. He is currently an Adjunct Assistant Professor at Trinity College, Dublin in the School of Biochemistry & Immunology.

Ian O’Connell, CFO

Ian O’Connell is an experienced financial professional with a depth of healthcare and public markets experience. In 2017 he co-founded Open Orphan plc, was made a Board Observer and as VP Corporate Development, he led the acquisition of hVIVO plc and the reverse takeover (RTO) of Venn Life Sciences plc. As a member of the core senior management team, Ian helped drive the company to its position today as a world leader in the testing of infectious and respiratory disease products using human challenge studies.

Prior to this, Ian worked closely with Cathal Friel and Amryt’s senior management on the establishment of Amryt Pharma plc. Ian gained Corporate Finance experience at both Raglan Capital and Deloitte Corporate Finance. Ian has a BSc (Hons) in Finance from University College Cork and is a Member of Chartered Accountants Ireland.

BASH is an acronym for Buy, Avoid, Sell and Hold a share in a company to be discussed during each panel.